Gen Plus

Gen-Plus GmbH & Co. KG is a privately-held, full-service CDMO headquartered in Munich, Germany, with operations in Cologne. Founded in 1999 and acquired by the Conscio Group in 2022, the company focuses on developing complex formulations and novel drug delivery technologies, including for narcotics and high-potent APIs. Its core business model is providing fee-for-service R&D and manufacturing, positioning it as a specialized innovation partner for the pharmaceutical industry. Gen-Plus is revenue-generating through its contract services and holds licenses for GMP manufacturing of clinical supplies from Phase I to IV.

Portfolio of >30 pharmaceutical technologies for formulation development, including nanotechnology, extrusion, lyophilization, amorphization, and personalized 2D/3D drug printing. Capabilities span solids, semi-solids, liquids, oral films, patches, and handling of high-potent APIs/narcotics.

Gen-Plus competes in a crowded global CDMO market against large players like Lonza, Catalent, and Recipharm, as well as numerous specialized smaller firms. Its differentiation hinges on niche expertise in advanced technologies like drug printing, extrusion, and handling of narcotics/high-potent compounds within a flexible, full-service model.